Since 2012, [18F]- and [68Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) entered early clinical development for PET imaging of PCa and showed immediate promise for sensitive and specific identification of local and distant sites of disease [16,17]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.